Prognostic factors in leukocytoclastic vasculitis: A clinicopathologic study of 160 patients

Archives of Dermatology

Volumn 134, Issue 3, 1998, Pages 309-315

  Sais, Gemma ^a,b   Vidaller, Antonio ^a   Jucglà, Anna ^a   Servitje, Octavio ^a   Condom, Enric ^a   Peyrí, Jordi ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOGLOBULIN; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; HISTOPATHOLOGY; HUMAN; LABORATORY DIAGNOSIS; LEUKOCYTOCLASTIC VASCULITIS; MALE; MORBIDITY; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SYSTEMIC VASCULITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; AUTOANTIBODIES; FEMALE; HUMANS; KIDNEY FAILURE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK FACTORS; SKIN; SKIN DISEASES, VASCULAR; VASCULITIS, HYPERSENSITIVITY;

EID: 0031913528     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.134.3.309     Document Type: Article

References (51)

1. Mackel SE, Jordon RE. Leukocytoclastic vasculitis: a cutaneous expression of immune complex disease. Arch Dermatol. 1982;118:296-301.
2. Jennette JC, Charles LA, Falk RJ. The neutrophil and its role in systemic vasculitis. In: Le Roy EC, ed. Systemic Vasculitis: The Biological Basis. New York, NY: Marcel Dekker Inc; 1992:65-92.
3. Fauci AS, Haynes BF, Katz P. NIH Conference: the spectrum of vasculitis: clinical, pathologic, immunologic, and therapeutic considerations. Ann Intern Med. 1978;89:660-676.
4. Jennette CJ, Milling DM, Falk RJ. Vasculitis affecting the skin: a review. Arch Dermatol. 1994;130:899-906.
5. Conn DL. Update on systemic necrotizing vasculitis. Mayo Clin Proc. 1989;64: 535-543.
6. Sais G, Vidaller A, Jucglà A, Condom E, Peyri J. Adhesion molecule expression and endothelial cell activation in cutaneous leukocytoclastic vasculitis: an immunohistological and clinical study on 42 cases. Arch Dermatol. 1997;133:443-450.
7. Sánchez NP, Van Hale HM, Su D. Clinical and histopathologic spectrum of necrotizing vasculitis: report of findings in 101 cases. Arch Dermatol. 1985;121: 220-224.
8. af Ekenstam E, Callen JP. Cutaneous leukocytoclastic vasculitis: clinical and laboratory features of 82 patients seen in private practice. Arch Dermatol. 1984;120: 484-489.
9. Cupps TR, Springer RM, Fauci AS. Chronic, recurrent, small-vessel cutaneous vasculitis: clinical experience in 13 patients. JAMA. 1982;247:1994-1998.
10. Gibson LE. Cutaneous vasculitis: approach to diagnosis and systemic associations. Mayo Clin Proc. 1990;65:221-229.
11. Somer T, Finegold S. Vasculitides associated with infections, immunization, and antimicrobial drugs. Clin Infect Dis. 1995;20:1010-1036.
12. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992;327:1490-1495.
13. Heart-Holmes M, Zahradka SL, Baethge BA, Wolf RE. Leukocytoclastic vasculitis associated with hepatitis C. Am J Med. 1991;90:765-766.
14. Misiani R, Bellavita P, Fenili D, et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med. 1992;117:573-577.
15. Popp JW, Harrist TJ, Dienstang JL, et al. Cutaneous vasculitis associated with acute and chronic hepatitis. Arch Intern Med. 1981;141:623-629.
16. Daoud MS, el-Azhary RA, Gibson LE, Lutz ME, Daoud S. Chronic hepatitis C, cryoglobulinemia and cutaneous necrotizing vasculitis. J Am Acad Dermatol. 1996; 34:219-223.
17. Karlsberg PL, Lee WM, Casey DL, Cockerell CJ, Cruz PD Jr. Cutaneous vasculitis and rheumatoid factor positivity as presenting signs of hepatitis C virus - induced mixed cryoglobulinemia. Arch Dermatol. 1995;131:1119-1123.
18. Gherardi R, Belec L, Mhiri C, et al. The spectrum of vasculitis in human immunodeficiency virus-infected patients: a clinicopathologic evaluation. Arthritis Rheum. 1993;36:1164-1174.
19. Calabresse LH, Estes M, Yen-Lieberman B, et al. Systemic vasculitis in association with human immunodeficiency virus infection. Arthritis Rheum. 1989;32: 569-576.
20. Sanchez Guerrero J, Gutierrez Urena J, Vidaller A, Reyes E, Iglesias A, Alarcon-Segovia D. Vasculitis as a paraneoplastic syndrome: report of 11 cases and review of the literature. J Rheumatol. 1990;17:1458-1462.
21. Greer JM, Longley S, Edwards NL, Elfenbein GJ, Panush RS. Vasculitis associated with malignancy: experience with 13 patients and literature review. Medicine. 1988;67:220-230.
22. Sais G, Vidaller A, Jucglà A, Gallardo F, Peyrí J. Colchicine in the treatment of cutaneous leukocytoclastic vasculitis: results of a prospective, randomized controlled trial. Arch Dermatol. 1995;131:1399-1402.
23. Conn DL. Overview of therapy and management of systemic vasculitis. In: Le Roy EC, ed. Systemic Vasculitis: The Biological Basis. New York, NY: Marcel Dekker Inc; 1992:547-574.
24. Hunder GH, Arend WP, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Arthritis Rheum. 1990;33:1065-1144.
25. Lie JT, Members and Consultants of the American College of Rheumatology Subcommittee on Classification of Vasculitis. Illustrated histopathologic classification criteria for selected vasculitis syndromes. Arthritis Rheum. 1990;33:1074-1087.
26. Prins M, Veraart JCJM, Vermeulen AHM, Hulsmans FHJ, Neumann HAM. Leukocytoclastic vasculitis induced by prolonged exercise. Br J Dermatol. 1996; 134:915-918.
27. Zax RH, Hodge SJ, Callen JP. Cutaneous leukocytoclastic vasculitis: serial histopathologic evaluation demonstrates the dynamic nature of the infiltrate. Arch Dermatol. 1990;126:69-72.
28. Gower RG, Sams WM Jr, Thorne EG. Leukocytoclastic vasculitis: sequential appearance of immunoreactants and cellular changes in serial biopsies. J Invest Dermatol. 1977;69:477-484.
29. Michel BA, Hunder GG, Bloch DA, Calabrese LH. Hypersensitivity vasculitis and Henoch-Schönlein purpura: a comparison between the 2 disorders. J Rheumatol. 1992;19:721-728.
30. Schroeter AL, Copeman PWM, Jordon RE, Sams WM Jr, Winkelman RK. Immunofluorescence of cutaneous vasculitis associated with systemic disease. Arch Dermatol. 1971;104:254-259.
31. Hené RJ, Velthuis P, van de Wiel A, Klepper D, Dorhout Mees EJ, Kater L. The relevance of IgA deposits in vessel walls of clinically normal skin: a prospective study. Arch Intern Med. 1986;146:745-749.
32. Helander SD, De Castro FR, Gibson LE. Henoch-Schönlein purpura: clinicopathologic correlation of cutaneous vascular IgA deposits and the relationship to leukocytoclastic vasculitis. Acta Derm Venereol. 1995;75:125-129.
33. Van Hale HM, Gibson LE, Schroeter AL. Henoch-Schönlein vasculitis: direct immunofluorescence study of uninvolved skin. J Am Acad Dermatol. 1986;15:665-670.
34. Tsai CC, Giangiacomo J, Zuckner J. Dermal IgA deposits in Henoch-Schönlein purpura and Berger's nephritis. Lancet. 1975;1:342-343.
35. Saklayen MG, Schroeter A, Nafs MA, Jalil K. IgA deposition in the skin of patients with alcoholic liver disease. J Cutan Pathol. 1996;23:12-18.
36. Hirbec G, Belghiti D, Wechsler J, Sobel A, Lagrue G. Immunofluorescence study of skin biopsy specimens from patients with chronic renal diseases. Kidney Int. 1977;12:374. Abstract.
37. Swerdlow MA, Chowdhury LN, Mishra V, Kavin H. IgA deposits in skin in alcoholic liver disease. J Am Acad Dermatol. 1983;9:232-236.
38. Thompson AJ, Chan Y-L, Woodroffe AJ. Vascular IgA deposits in clinically normal skin of patients with renal disease. Pathology. 1980;12:407-413.
39. Van der Woude FJ, Lobato S, Permin H, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet. 1985;1:425-429.
40. Jennette JC, Falk RJ. Antineutrophil cytoplasmic antibodies and associated diseases: a review. Am J Kidney Dis. 1990:15:517-529.
41. Cohen Tervaert JW, Goldschmeding R, Elema JD, et al. Association of autoantibodies to myeloperoxidase with different forms of vasculitis. Arthritis Rheum. 1990;33:1264-1272.
42. Venning MC, Arfeen S, Bird AG. Antibodies to neutrophil cytoplasmic antigen in systemic vasculitis. Lancet. 1987;2:850.
43. Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med. 1988;318:1651-1657.
44. Savage COS, Winearls CG, Jones S, Marshall PD, Lockwood CM. Prospective study of radioimmunoassay for antibodies against neutrophil cytoplasm in diagnosis of systemic vasculitis. Lancet. 1987;1:1389-1393.
45. Gross WL, Schmitt WH, Csernok E. Antineutrophil cytoplasmic autoantibody-associated diseases: a rheumatologist's perspective. Am J Kidney Dis. 1991;18: 175-179.
46. Kemmett D, Harrison DJ, Hunter JAA. Antibodies to neutrophil cytoplasmic antigens: a serologic marker for Sweet's syndrome. J Am Acad Dermatol. 1991; 24:967-969.
47. Kemmett D, Hunter JAA. Sweet's syndrome: a clinicopathologic review of twenty-nine cases. J Am Acad Dermatol. 1990;23:503-507.
48. Burrows NP, Lockwood CM. Antineutrophil cytoplasmic antibodies and their relevance to the dermatologist. Br J Dermatol. 1995;132:173-181.
49. Irvine AD, Bruce IN, Walsh M, Burrows D, Handley J. Dermatological presentation of disease associated with antineutrophil cytoplasmic antibodies: a report of two contrasting cases and a review of the literature. Br J Dermatol. 1996;134: 924-928.
50. Dolman KM, Gans ROB, Verbaat TJ, et al. Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet. 1993;342: 651-652.
51. Kawachi Y, Nukaga H, Hoshino M, Iwata M, Otsuka F. ANCA-associated vasculitis and lupus-like syndrome caused by methimazole. Clin Exp Dermatol. 1995; 20:345-347.